Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety".

Yamamoto, Hiroyasu; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Akizawa, Tadao

Yamamoto, Hiroyasu; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Akizawa, Tadao.

Afiliación

Yamamoto H; Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Nobori K; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Matsuda Y; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayashi Y; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayasaki T; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Akizawa T; Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Am J Nephrol ; 52(12): 977-978, 2021.

Article en En | MEDLINE | ID: mdl-34727543

Asunto(s)

Anemia; Inhibidores de Prolil-Hidroxilasa; Humanos; Prolina Dioxigenasas del Factor Inducible por Hipoxia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Prolil-Hidroxilasa / Anemia Límite: Humans Idioma: En Revista: Am J Nephrol Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google